valu usd unless otherwis note
rais number solid execut set-up
close favor
view report came first-tim guidanc
expect bullish manag commentari
call add comfort around near-term trend head
toward close overal leav quarter
number move higher target
leav number push higher reflect strong
outlook driven growth key product particularli skyrizi/humira
guidanc around core product larg favor hem/
onc franchis expect grow year-over-year captur street
long-term target re-affirmed humira guid
importantli skyrizi/rinvoq guid billion far consensu
overal stand-alone ep estim move
earli calquenc made modest inroad
sinc approv cll low singl digit share
share though half previous fail imbruvica
compani acknowledg slow start orilissa guidanc far
expect though benefit launch
uterin indic year chang strategi around activ
deal on-track close end newco guidanc
follow thereaft manag also indic complet
integr plan confirm synergi object expect
on-track meet exceed billion synergi target report
indic prior quarter slightli ahead
expect acquisit strateg deviat
rel peer increasingli unload legaci asset
manag see impedi futur
growth profil said post-clos could see potenti strateg
prune newco addit busi develop ahead
like remain focu
leav outlook drive near-term confid bigger
hurdl meaning valuat re-rat growth
valuat reflect low expect price-to-earnings newco ep
abil execut within franchis clear said us
humira loe remain debat manag point ou
eros remain volum compani expect
shape eros curv us fare least well
better note could step-down overal
busi would return quickli growth thereaft
unclear long-term newco guidanc given follow deal close
focus strateg action could focu portfolio
core growth pillar augment newco growth profil
price prior trade day market close estimate unless otherwis note
invest thesi multi-year outlook
pressur compani work
us humira loss exclus loe replac
gap lower-margin asset announc allergan
acquisit expect close legaci
portfolio struggl strateg fit
allergan deal serv help combin compani
navig loe provid suffici cash flow support
continu strateg deploy capit thesi base
follow key point support sector perform
allergan acquisit help compani navig
humira cliff see opportun divest lower
growth asset addit provid attract add
product dilut growth profil combin
compani said see potenti futur strateg
action could creat valu ie divest non-cor
franchis bolster cash flow near-term
high growth product insuffici drive top-line
growth combin compani pressur outer-
year margin expect combin newco drive flat
top-line growth margin pressur
humira loe allergan product mix impact
growth lower-margin hem/onc franchis
limit meaning busi develop abbvi
digest allergan deal focus debt paydown
commit grow dividend also pay
billion debt end
paydown beyond flexibl around
smaller deal expect see execut anyth
meaning near-term could move needl
potenti catalyst close allergan acquisit
sever data read focu rinvoq ph data
atop derm skyrizi motiv data
cd induct bi voltaire-x interchang studi
read-out biosimilar humira head-to-head calquence/
imbruvica data r/r cll
risk thesi delay close allergan deal
competit risk particularli around hem-onc franchis
botox slower uptak key grower regulatory/
polit risk read-through price
bloomberg capit market estim upside/downside/target
base case scenario see price target impli
price-to-earnings pro-forma ep
assum deal close allergan specif
addit accret built estim expect
limit impact hem-onc franchis competit
strong uptak key growth product skyrizi
upsid case scenario see price target impli
price-to-earnings pro-forma ep
faster uptak key growth product skyrizi
assum deal close allergan addit
accret built estim
lower humira eros follow us loss exclus
expect
limit impact hem-onc franchis competit
downsid case scenario see price target
impli price-to-earnings pro-forma ep
sluggish uptak key growth product skyrizi
assum prolong deal closur allergan and/or
stringent ftc divestitur requir expect
aggress humira eros follow us loss
exclus expect
meaning impact hem-onc franchis competit
faster convers anticip
exhibit
 incom guid appr op growth product profit guid guid guid salesoper incom guid sale expens guid billionnet foreign exchang incom expens interest expens incom tax tax guid adjust tax rate earn ep guid share share guid flatdividend per increas announc yield price dividend yield assum annual increasesebitda guid guid guid salesoper guid sale guid profit analysi guid appr op growth share per inc
price target base equal ev/ebitda price-to-earnings estim reflect
close allergan acquisit use multipl respect
reflect meaning discount histor industri averag adjust us loss
exclus humira impli return price target support sector
risk rate price target
risk rate price target includ limit tail valu risk
humira still meaning contributor combin compani acquisit risk work
close integr allergan transact largest deal histori
regulatory/polit risk broadli applic sector particularli around pricing/
global biopharmaceut compani base chicago il spun
abbott becam independ publicly-trad compani compani
track record acquisit pharmacycl stemcentrx
announc acquisit allergan expect close upon
close allergan transact combin compani focus immunolog
hematolog oncolog medic aesthet neurosci franchis
analyst respons prepar research report receiv compens base upon variou factor includ
total revenu member compani capit market affili portion gener
invest bank activ member compani capit market affili
pleas note current conflict disclosur may differ public date set forth
